Literature DB >> 12235104

Do NKT cells control autoimmunity?

Lucienne Chatenoud1.   

Abstract

Mesh:

Substances:

Year:  2002        PMID: 12235104      PMCID: PMC151140          DOI: 10.1172/JCI16625

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  26 in total

Review 1.  Tolerance to islet autoantigens in type 1 diabetes.

Authors:  J F Bach; L Chatenoud
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

2.  Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse.

Authors:  F D Shi; M Flodstrom; B Balasa; S H Kim; K Van Gunst; J L Strominger; S B Wilson; N Sarvetnick
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

3.  Murine CD1d-restricted T cell recognition of cellular lipids.

Authors:  J E Gumperz; C Roy; A Makowska; D Lum; M Sugita; T Podrebarac; Y Koezuka; S A Porcelli; S Cardell; M B Brenner; S M Behar
Journal:  Immunity       Date:  2000-02       Impact factor: 31.745

4.  The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice.

Authors:  S Hong; M T Wilson; I Serizawa; L Wu; N Singh; O V Naidenko; T Miura; T Haba; D C Scherer; J Wei; M Kronenberg; Y Koezuka; L Van Kaer
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

5.  Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes.

Authors:  S Sharif; G A Arreaza; P Zucker; Q S Mi; J Sondhi; O V Naidenko; M Kronenberg; Y Koezuka; T L Delovitch; J M Gombert; M Leite-De-Moraes; C Gouarin; R Zhu; A Hameg; T Nakayama; M Taniguchi; F Lepault; A Lehuen; J F Bach; A Herbelin
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

6.  A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells.

Authors:  K Miyamoto; S Miyake; T Yamamura
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

7.  IL-7 reverses NK1+ T cell-defective IL-4 production in the non-obese diabetic mouse.

Authors:  J M Gombert; E Tancrède-Bohin; A Hameg; M C Leite-de-Moraes; A Vicari; J F Bach; A Herbelin
Journal:  Int Immunol       Date:  1996-11       Impact factor: 4.823

8.  CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes.

Authors:  B Wang; Y B Geng; C R Wang
Journal:  J Exp Med       Date:  2001-08-06       Impact factor: 14.307

9.  Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis.

Authors:  A K Singh; M T Wilson; S Hong; D Olivares-Villagómez; C Du; A K Stanic; S Joyce; S Sriram; Y Koezuka; L Van Kaer
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

10.  Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis.

Authors:  A W Jahng; I Maricic; B Pedersen; N Burdin; O Naidenko; M Kronenberg; Y Koezuka; V Kumar
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

View more
  4 in total

1.  Invariant natural killer T cells in lupus patients promote IgG and IgG autoantibody production.

Authors:  Lei Shen; Hong Zhang; Maria Caimol; Claudia J Benike; Eliza F Chakravarty; Samuel Strober; Edgar G Engleman
Journal:  Eur J Immunol       Date:  2014-11-27       Impact factor: 5.532

Review 2.  Checkpoints in lymphocyte development and autoimmune disease.

Authors:  Harald von Boehmer; Fritz Melchers
Journal:  Nat Immunol       Date:  2009-12-17       Impact factor: 25.606

Review 3.  Cell-based interventions to halt autoimmunity in type 1 diabetes mellitus.

Authors:  A E Barcala Tabarrozzi; C N Castro; R A Dewey; M C Sogayar; L Labriola; M J Perone
Journal:  Clin Exp Immunol       Date:  2013-02       Impact factor: 4.330

4.  Impact of Low-Dose Occupational Exposure to Ionizing Radiation on T-Cell Populations and Subpopulations and Humoral Factors Included in the Immune Response.

Authors:  Ilona Gyuleva; Jana Djounova; Ivanka Rupova
Journal:  Dose Response       Date:  2018-08-15       Impact factor: 2.658

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.